Clinical Trial Update: The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study [Phase 1]

View source ↗

Summary

Phase I pilot pharmacokinetic study evaluating extended-duration high-dose cefixime for Neisseria gonorrhoeae with decreased susceptibility.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gonorrhea

Drugs mentioned

• CEFIXIME (cefixime)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Gonorrhoea | Phase 1 | Status: COMPLETED